Predicting Antibody Responses to Type V GBS-TT Conjugate Vaccine Using Computational Modelling

25th International Conference on Computational Science - 2025 Singapore

Matheus Ribeiro, Bárbara Quintela, **Ruy Freitas Reis**, Rodrigo dos Santos and Marcelo Lobosco
July 7–9th, 2025

Pós-Graduação em Modelagem Computacional Departamento de Ciência da Computação Universidade Federal de Juiz de Fora

Overview



- 1. Introduction
- 2. Background

- 3. Methods
- 4. Results and Discussion
- 5. Conclusion and Future Work

Introduction

The Challenge of GBS



- Group B Streptococcus (GBS) is a leading cause of neonatal mortality and morbidity.
 - 410,000 cases worldwide, leading to 147,000 stillbirths and infant deaths
- It can cause severe infections like sepsis, pneumonia, and meningitis in newborns.
- Current prevention relies on maternal screening and intrapartum antimicrobial prophylaxis (IAP).
- Maternal vaccination is a promising strategy, offering transplacental transfer of antibodies for protection.
- The Type V GBS-TT conjugate vaccine is a significant development.

The Role of Computational Models



- Computational models are valuable tools in vaccine research.
- They simulate disease dynamics, immune responses, and vaccine effects within a controlled virtual environment.
- Such models enable rapid exploration of scenarios, including variations in vaccine dosage and administration schedules.
- Ordinary differential equation (ODE) models offer a balance between interpretability and computational efficiency.
- In this study, we extend an established ODE model to evaluate the Type V GBS-TT conjugate vaccine.

Background

GBS and Immune Response



- GBS (Streptococcus agalactiae) is a common bacterium and a major cause of neonatal infections.
- The innate immune system acts as the first line of defense, involving cells such as neutrophils and macrophages.
- The adaptive immune system produces specific antibodies against GBS antigens, primarily targeting the polysaccharide capsule.
- Vaccines mimic natural infection to elicit memory immune responses without causing disease.
- The Type V GBS-TT conjugate vaccine uses capsular polysaccharides (CPS) conjugated with tetanus toxoid (TT) to enhance immunogenicity.

Vaccine Dosages and Antibody Production



- A study by Baker et al. ¹ evaluated the Type V GBS-TT conjugate vaccine at different dosages in healthy adults.
- The vaccine elicited a dose-dependent immune response, with higher doses inducing greater production of specific antibodies.

¹Baker *et al.*, Dose–response to type V group B streptococcal polysaccharide–tetanus toxoid conjugate vaccine in healthy adults. *Vaccine*, 25(1), pp. 55–63, Jan 2007.

Vaccine Dosages and Antibody Production






Figure 1: Sum of IgG, IgM and IgA for the distinct vaccines. Cohort data from Baker *et al.*

Methods

Mathematical Model for Immune Response




- The model is a system of ordinary differential equations (ODEs), adapted from Bonin et al. ²
- It describes interactions among:
 - Vaccine particles (Vp),
 - Antigen-presenting cells (naive Ap, mature Apm),
 - Lymphocytes (Thn, The, Tkn, Tke, B, Bm, Ps, Pl),
 - Antibodies (A).
- The model includes terms for vaccine elimination, cell maturation, activation, replication, differentiation, and decay.

²Bonin *et al.*, Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, revaccination and dose-response in adults, and studies with immunocompromised individuals. *BMC Bioinformatics*, 21(S17), Dec 2020.

Model scheme







$$\frac{d}{dt}V_{\mathbf{p}} = -\underbrace{\begin{bmatrix} c_{v1}V_{\mathbf{p}} \\ c_{v2} + V_{\mathbf{p}} \end{bmatrix}}_{\mathbf{l}} - k_{v1}V_{\mathbf{p}}A - k_{v2}V_{\mathbf{p}}T_{E}$$



$$\frac{d}{dt}V_{\rm p} = - \ \frac{c_{v1}V_{\rm p}}{c_{v2} + V_{\rm p}} - \underbrace{k_{v1}V_{\rm p}A}_{\text{l}} - k_{v2}V_{\rm p}T_E$$
 Neutralization by antibodies



$$\frac{d}{dt}V_{\mathbf{p}} = -\frac{c_{v1}V_{\mathbf{p}}}{c_{v2} + V_{\mathbf{p}}} - k_{v1}V_{\mathbf{p}}A - k_{v2}V_{\mathbf{p}}T_{E}$$

$$\downarrow$$
Elimination by T killer cells

Cohort Data and Calibration



- Cohort data were extracted from a phase 1 trial comparing the Type V GBS-TT conjugate vaccine (V-TT) with an unconjugated Type V capsular polysaccharide (V-CPS) vaccine.
- Healthy adults (aged 18–50 years) were assigned to four vaccine groups.
- Blood samples were collected at baseline and at 4, 8, 26, and 52 weeks post-vaccination.

Cohort Data and Calibration



- Type V CPS-specific antibodies (IgG, IgA, and IgM) were quantified using ELISA.
- Differential Evolution (DE) was employed to calibrate seven key model parameters.
- The objective function minimized the L₂ norm of the relative error between observed and simulated antibody levels.

Results and Discussion

Model Accuracy Across Vaccine Doses






Figure 2: Unconjugated CPS: $37\mu g$

Model Accuracy Across Vaccine Doses (Cont.)






Figure 3: V-TT: $38.5\mu g \ CPS/17.0\mu g \ TT$

Model Accuracy Across Vaccine Doses (Cont.)






Figure 4: V-TT: $9.6\mu g$ CPS/ $4.3\mu g$ TT

Model Accuracy Across Vaccine Doses (Cont.)






Figure 5: V-TT: $2.4\mu g$ CPS/ $1.1\mu g$ TT

Model Accuracy Across Vaccine Doses



- The model accurately reproduced the dose-dependent antibody response observed in the clinical trial.
- Higher CPS doses elicited stronger and more sustained antibody levels.
- The highest V-TT dose (38.5 μg CPS / 17.0 μg TT) showed near-perfect alignment with cohort data.
- Lower doses (2.4 μg CPS / 1.1 μg TT) exhibited greater discrepancies, with simulated titers consistently falling below the geometric mean titer (GMT).
- These deviations suggest opportunities for model refinement.

Calibration Success and Parameter Differences



- The DE algorithm successfully calibrated seven key parameters to fit the model to cohort data for both unconjugated CPS and conjugated V-TT vaccines.
- Significant differences were observed between the two vaccine formulations, reflecting distinct immunological mechanisms.
- For the V-TT vaccine, the antigen-presenting cell maturation rate (β_{ap}) was 93 times higher than for the unconjugated vaccine.
 - This supports the adjuvant effect of tetanus toxoid.

Calibration Success and Parameter Differences



- The antibody-mediated vaccine clearance rate (k_{v1}) was approximately 1,700 times higher for the conjugated vaccine, suggesting more effective neutralization of vaccine particles.
- The short-lived plasmocyte decay rate (δ_{ps}) remained consistent across formulations.
- The antibody decay rate (δ_A) was slightly higher for the V-TT conjugate vaccine.

Conclusion and Future Work

Conclusions



- Developed a computational model to simulate the immune response to the Type V GBS-TT conjugate vaccine.
- Successfully reproduced clinical trial data across multiple dosage groups.
- Calibration using Differential Evolution provided mechanistic insights into dose-dependent efficacy.
- The conjugated V-TT vaccine elicited a more robust and sustained antibody response than the unconjugated CPS formulation.
- Enhanced APC maturation and accelerated antibody-mediated clearance emerged as key contributors to the superior immune response.

Future Work



- Incorporate additional parameters into the calibration process to improve model precision.
- Explore uncertainty quantification to assess confidence in model predictions.
- Integrate patient-specific immune profiles to enable personalized dosing strategies, especially for high-risk populations.

Acknowledgements



Obrigado! Thanks!



